NFKB1 and ischemic stroke: Taken together, these findings indicate that CSO treatment inhibited TLR4-mediated microglial activation and TNF-α secretion, thereby inhibiting NF-κB-mediated A1 astrocyte activation and reducing C3d expression and secretion, ultimately alleviating neuronal damage induced by ischemic stroke injury (Fig. 8).